LinkedIn

 آمار

تعداد نشریات20
تعداد شماره‌ها1,089
تعداد مقالات9,995
تعداد مشاهده مقاله26,434,238
تعداد دریافت فایل اصل مقاله7,285,536
Moustafa, Ehab, Hassan, Elham, Mahmoud, Mohamed, Mahmoud, Amal, Ghaliony, Mohamed. (1401). Deranged Lipid Profiles and Hepatocellular Carcinoma: Clinical Significance and Association. سامانه مدیریت نشریات علمی, 13(2), 275-284. doi: 10.30476/mejc.2021.86476.1346
Ehab Fawzy Abdo Moustafa; Elham Ahmed Hassan; Mohamed Mustafa Mahmoud; Amal A. Mahmoud; Mohamed AA Ghaliony. "Deranged Lipid Profiles and Hepatocellular Carcinoma: Clinical Significance and Association". سامانه مدیریت نشریات علمی, 13, 2, 1401, 275-284. doi: 10.30476/mejc.2021.86476.1346
Moustafa, Ehab, Hassan, Elham, Mahmoud, Mohamed, Mahmoud, Amal, Ghaliony, Mohamed. (1401). 'Deranged Lipid Profiles and Hepatocellular Carcinoma: Clinical Significance and Association', سامانه مدیریت نشریات علمی, 13(2), pp. 275-284. doi: 10.30476/mejc.2021.86476.1346
Moustafa, Ehab, Hassan, Elham, Mahmoud, Mohamed, Mahmoud, Amal, Ghaliony, Mohamed. Deranged Lipid Profiles and Hepatocellular Carcinoma: Clinical Significance and Association. سامانه مدیریت نشریات علمی, 1401; 13(2): 275-284. doi: 10.30476/mejc.2021.86476.1346

Deranged Lipid Profiles and Hepatocellular Carcinoma: Clinical Significance and Association

Middle East Journal of Cancer
مقاله 8، دوره 13، شماره 2 - شماره پیاپی 50، تیر 2022، صفحه 275-284    اصل مقاله (724.86 K)
نوع مقاله: Original Article(s)
شناسه دیجیتال (DOI): 10.30476/mejc.2021.86476.1346
نویسندگان
Ehab Fawzy Abdo Moustafa1؛ Elham Ahmed Hassan* 1؛ Mohamed Mustafa Mahmoud2؛ Amal A. Mahmoud3؛ Mohamed AA Ghaliony1
1Department of Gastroenterology and Tropical Medicine, Faculty of Medicine, Assiut University, Assiut, Egypt
2Fever Hospital, Ministry of Health, Sohag, Egypt
3Department of Clinical Pathology, Faculty of Medicine, Assiut University, Assiut, Egypt
چکیده
Background: The increasing incidence of hepatocellular carcinoma (HCC) is a challenging health problem worldwide with poor prognosis and limited treatment options. The association between metabolic factors and HCC has been documented, however, there is a shortage of data about this association in our locality. Therefore, we aimed to determine the pattern of lipid profile in cirrhotic patients with HCC and investigate the association between dyslipidemia and HCC.
Method: In this case-control hospital-based study, serum lipid profile [total cholesterol, triglycerides, low-density lipoprotein (LDL), high-density lipoprotein (HDL), and very-low-density lipoprotein (VLDL)] was determined in 100 patients with cirrhosis and 100 patients with cirrhosis and HCC. Multivariate analysis of HCC risk factors was done.
Results: Metabolic syndrome, hypertriglyceridemia, hypercholesterolemia, high LDL, and combined dyslipidemia were significantly more frequent in HCC patients than non-HCC patients. Low HDL and dyslipidemia were significantly associated with the late HCC stages and LDL levels were significantly correlated with α- fetoprotein levels. There was a tendency towards increasing the values of the other lipid parameters in advanced stages. Metabolic syndrome and combined dyslipidemia were associated with HCC risk.
Conclusion: Deranged lipid profiles were common in HCC patients. Metabolic syndrome and combined dyslipidemia could be potential risk factors for HCC and may offer a useful strategy for risk stratification; thus, their control can reduce the HCC burden.
کلیدواژه‌ها
Dyslipidemias؛ Hepatocellular carcinoma (HCC)؛ Metabolic syndrome؛ Risk factors
اصل مقاله

How to cite this article:

Abdo Moustafa EF, Hassan EA, Mahmoud MM, Mahmoud AA, Ghaliony MAA. Deranged lipid profiles and hepatocellular carcinoma: clinical significance and association. Middle East J Cancer. 2022;13(2):275-84. doi: 10.30476/mejc.2021.86476.1346.

مراجع
  1. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015; 65(2): 87-108. doi: 10.3322/caac.21262.
  2. Forner A, Reig M, Bruix J. Hepatocellular carcinoma. Lancet. 2018;391(10127):1301-14. doi: 10.1016/S0140-6736(18)30010-2.
  3. Villanueva A. Hepatocellular carcinoma. N Engl J Med. 2019;380(15):1450-62. doi: 10.1056/NEJMra1713263.
  4. Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136(5):E359-86. doi: 10.1002/ijc.29210.
  5. Le GM, Biagini MR, Tarocchi M, Polvani S, Galli A. Chemotherapy for hepatocellular carcinoma: the present and the future. World J Hepatol. 2017;9(21):907-20. doi: 10.4254/wjh.v9.i21.907.
  6. Argyrou C, Moris D, Vernadakis S. Hepatocellular carcinoma development in non-alcoholic fatty liver disease and non-alcoholic steatohepatitis. Is it going to be the “Plague” of the 21st century? A literature review focusing on pathogenesis, prevention and treatment. J BUON. 2017;22(1):6-20.
  7. Reeves HL, Zaki MYW, Day CP. Hepatocellular carcinoma in obesity, type 2 diabetes, and NAFLD. Dig Dis Sci. 2016;61(5):1234-45. doi: 10.1007/s10620-016-4085-6.
  8. Yang JD, Mohamed HA, Cvinar JL, Gores GJ, Roberts LR, Kim WR. Diabetes mellitus heightens the risk of hepatocellular carcinoma except in patients with hepatitis c cirrhosis. Am J Gastroenterol. 2016;111(11):1573-80. doi: 10.1038/ajg.2016.330.
  9. Lewis GF, Rader DJ. New insights into the regulation of HDL metabolism and reverse cholesterol transport. Circ Res. 2005;96(12):1221-32. doi: 10.1161/01.RES.0000170946.56981.5c.
  10. Fiorenza AM, Branchi A, Sommariva D. Serum lipoprotein profile in patients with cancer. A comparison with non-cancer subjects. Int J Clin Lab Res. 2000;30(3):141-5. doi: 10.1007/s005990070013.
  11. Muntoni S, Atzori L, Mereu R, Satta G, Macis MD, Congia M, et al. Serum lipoproteins and cancer. Nutr Metab Cardiovasc Dis. 2009;19(3):218-25. doi:10.1016/j.numecd.2008.06.002.
  12. Usman H, Rashid R, Ameer F, Iqbal A, Zaid M. Revisiting the dyslipidemia associated with acuteleukemia. Clin Chim Acta. 2015;444:43-9. doi:10.1016/j.cca.2015.01.038.
  13. Akinyemiju T, Abera S, Ahmed M, Alam N, Alemayohu MA, Allen C, et al. The burden of primary liver cancer and underlying etiologies from 1990 to 2015 at the global, regional, and national level. JAMA Oncol. 2017;3(12):1683-91. doi:10.1001/jamaoncol.2017.3055.
  14. El Zayadi AR, Badran HM, EMF B, Attia Mel- D, Shawky S, Mohamed MK, et al. Hepatocellular carcinoma in Egypt: a single center study over a decade. World J Gastroenterol. 2005;11(33):5193-8.doi: 10.3748/wjg.v11.i33.5193.
  15. Bruix J, Sherman M. Management of hepatocellular carcinoma: an update. Hepatology. 2011;53(3):1020-2. doi: 10.1002/hep.24199.
  16. Bruix J, Sherman M, Llovet JM, Beaugrand M, Lencioni R, Burroughs AK, et al. EASL Panel of Experts on HCC. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol. 2001;35(3):421-30. doi: 10.1016/s0168-8278(01)00130-1.
  17. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of The National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult treatment panel III). JAMA. 2001;285(19):2486-97. doi: 10.1001/jama.285.19.2486.
  18. George P, Ludvik B. Lipids and diabetes. J Clin Basic Cardiol. 2000;3(3):159-62.
  19. Grundy SM, Cleeman JI, Merz CN, Brewer HB Jr, Clark LT, Hunninghake DB, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation. 2004;110(2):227-39. doi:10.1161/01.CIR.0000133317.49796.0E.
  20. Esposito K, Chiodini P, Colao A, Lenzi A, Giugliano D. Metabolic syndrome and risk of cancer: a systematic review and meta-analysis. Diabetes Care. 2012;35(11):2402-11. doi: 10.2337/dc12-0336.
  21. Russo A, Autelitano M, Bisanti L. Metabolic syndrome and cancer risk. Eur J Cancer. 2008;44(2):293-7. doi: 10.1016/j.ejca.2007.11.005.
  22. Welzel TM, Graubard BI, Zeuzem S, El-Serag HB, Davila JA, McGlynn KA. Metabolic syndrome increases the risk of primary liver cancer in the United States: a study in the SEER-Medicare database. Hepatology. 2011;54(2):463-71. doi: 10.1002/hep.24397.
  23. Fernandes JV, Cobucci RN, Jatoba CA, Fernandes TA, de Azevedo JW, de Araujo JM. The role of the mediators of inflammation in cancer development. Pathol Oncol Res. 2015;21(3):527-34. doi: 10.1007/s12253-015-9913-z.
  24. Sohda T, Iwata K, Kitamura Y, Suzuki N, Takeyama Y, Irie M, et al. Reduced expression of low-density lipoprotein receptor in hepatocellular carcinoma with paraneoplastic hypercholesterolemia. J Gastroenterol Hepatol. 2008;23(7Pt2):e153-e6. doi:10.1111/j.1440-1746.2007.05115.x.
  25. Alsabti' EAK. Serum lipids in hepatoma. Oncology. 1979;36(1):11-4. doi:10.1159/000225310.
  26. Qu Q, Wang S, Chen S, Zhou L, Rui JA. Prognostic role and significance of paraneoplastic syndromes in patients with hepatocellular carcinoma. Am Surg. 2014;80(2):191-6.
  27. Alpert ME, Hutt MSR, Davidson CS. Primary hepatoma in Uganda. A prospective clinical and epidemiologic study of forty six patients. AM J Med. 1969;46(5):794-802. doi: 10.1016/0002-9343(69)90030-8.
  28. Luo JC, Hwang SJ, Wu JC, Lai CR, Li CP, Chang FY, et al. Clinical characteristics and prognosis of hepatocellular carcinoma patients with paraneoplastic syndromes. Hepatogastroenterology. 2002;49(47):1315-9.
  29. Ahaneku JE, Olubuyide IO, Taylor GO, Agbedana EO. Abnormal lipid and lipoprotein patterns in liver cirrhosis with and without hepatocelluiar carcinoma. J Pak Med Assoc. 1992;42(11):260-3.
  30. Motta M, Giugno I, Ruello P, Pistone G, Di Fazio I, Malaguarnera M. Lipoprotein (a) behavior in patients with hepatocellular carcinoma. Minerva Med. 2001;92(5):301-5.
  31. Casey PJ, Solski PA, Der CJ, Buss JE. p21ras is modified by a farnesyl isoprenoid. Proc Natl Acad Sci (USA). 1989;86(21):8323-7. doi: 10.1073/pnas.86.21.8323.
  32. Ooi K, Shiraki K, Sakurai Y, Morishita Y, Nobori T. Clinical significance of abnormal lipoprotein patterns in liver diseases. Int J Mol Med. 2005;15(4):655-60.
  33. Kita T, Brown MS, Bilheimer DW, Goldstein JL. Delayed clearance of very low density and intermediate density lipoproteins with enhanced conversion to low density lipoprotein in WHHL rabbits. Proc Natl Acad Sci (USA). 1982;79(18):5693-7. doi:10.1073/pnas.79.18.5693.
  34. Jiang J, Nilsson-Ehle P, Xu N. Influence of liver cancer on lipid and lipoprotein metabolism. Lipids Health Dis. 2006;3;5:4. doi: 10.1186/1476-511X-5-4.
  35. Kanel GC, Radvan G, Peters RL. High-density lipoprotein cholesterol and liver disease. Hepatology. 1983;3(3):343-8. doi: 10.1002/hep.1840030311.
  36. Huang J, Li L, Lian J, Schauer S, Vesely PW, Kratky D, et al. Tumor-induced hyperlipidemia contributes to tumor growth. Cell Rep. 2016;15(2):336-48. doi:10.1016/j.celrep.2016.03.020.
  37. Moucari R, Asselah T, Cazals-Hatem D. Insulin resistance in chronic hepatitis C: association with genotypes 1 and 4, serum HCV RNA, and liver fibrosis. Gastroenterology. 2008;134(2):416-23. doi:10.1053/j.gastro.2007.11.010.
  38. Wedemeyer I, Bechmann LP, Odenthal M, Jochum C, Marquitan G, Drebber U, et al. Adiponectin inhibits steatotic CD95/Fas up-regulation by hepatocytes: therapeutic implications for hepatitis C. J Hepatol. 2009;50(1):140-9. doi:10.1016/j.jhep.2008.08.023.
  39. Serfaty L, Poujol-Robert A, Carbonell N, Chazouilleres O, Poupon RE, Poupon R. Effect of the interaction between steatosis and alcohol intake on liver fibrosis progression in chronic hepatitis C. Am J Gastroenterol. 2002;97(7):1807-12. doi: 10.1111/j.1572-0241.2002.05793.x.
  40. Menendez JA, Lupu R. Fatty acid synthase and the lipogenic phenotype in cancer pathogenesis. Nat Rev Cancer. 2007;7(10):763-77. doi: 10.1038/nrc2222.
آمار
تعداد مشاهده مقاله: 1,940
تعداد دریافت فایل اصل مقاله: 1,798


سامانه مدیریت نشریات علمی. قدرت گرفته از سیناوب